The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in patients with Rheumatoid Arthritis.

This study is comprised of 2 periods:

Period 1 - unblinded treatment for up to 240 weeks for patients who enroll from Study H9B-MC-BCDO (BCDO) (NCT01202760) or Study H9B-MC-BCDV (BCDV) (NCT01202773) or up to 168 weeks for patients who enroll from Study H9B-MC-BCDM (BCDM) (NCT01198002).

Period 2 - 48 week post treatment follow up

Read more: http://www.clinicaltrials.gov/ct2/show/NCT01215942?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30